Clinical Trials Directory

Trials / Unknown

UnknownNCT01725906

Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication

Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
450 (estimated)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
20 Years – 85 Years
Healthy volunteers
Not accepted

Summary

We aimed to compare the efficacy of genotypic resistance guided sequential therapy vs. empiric therapy in the third line therapy. Factors affecting the eradication rates, including the antibiotic resistance, CYP2C19 polymorphism, CagA and VacA status will also be assessed.

Detailed description

The primary aim of this study is to compare the regimens selected using either one of the method (1) genotypic resistance guided versus (2) medication history guided therapy. (rather than to compare the efficacy of any drugs).

Conditions

Interventions

TypeNameDescription
DRUGempirical therapy1. Nexium (esomeprazole), 40mg, bid, 14 days, plus 2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus 3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs 4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14
DRUGGenotypic resistance guided therapy1. Nexium (esomeprazole), 40mg, bid, 14 days, plus 2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus 3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs 4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14

Timeline

Start date
2012-11-01
Primary completion
2017-05-01
Completion
2017-12-01
First posted
2012-11-14
Last updated
2017-05-08

Locations

2 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01725906. Inclusion in this directory is not an endorsement.